Should drugmakers amp up security at leaked plants?

When WikiLeaks leaks, it's more like a flood, and this time, it's even covering pharma. The latest revelations to float to the surface include a list of "critical" drug and vaccine facilities in countries around the world. Among these key plants are Big Pharma facilities in Europe, Latin America, Canada and Australia that are operated by drugmakers including Roche and GlaxoSmithKline ($GSK).

Destruction of those facilities would be a threat to national security and/or public health and safety, the government decided in 2008. That's because they make essential products, such as smallpox vaccines, diabetes drugs, and flu treatments (Roche's Tamiflu and GSK's Relenza among them). Plants turning out insulin for Sanofi-Aventis ($SNY) and Novo Nordisk ($NVO) made the list, as did facilities run by Genzyme ($GENZ) and Novartis.

Government officials decried the identification of these critical facilities, calling it "irresponsible" and even "bordering on criminal," ostensibly because the list puts a bulls-eye on every one of them. In fact, one commentator suggested that companies double-check their security procedures at the named plants, InPharm notes. If drugmakers are doing so, they aren't saying. But then again, they aren't saying much of anything about the leaks.

- read the InPharm story

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.